Immunogenicity Assessment of Recombinant Human C1-Inhibitor: An Integrated Analysis of Clinical Studies

ISSN： 1173-8804

Source： BioDrugs, Vol.26, Iss.5, 2012-10, pp. : 303-313

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recombinant Human C1 Inhibitor (Conestat Alfa): In the Treatment of Angioedema Attacks in Hereditary Angioedema

By Plosker Greg L.

BioDrugs, Vol. 26, Iss. 5, 2012-10 ,pp. : 315-323

Adis International

Access to resources Recommend Favorite

Recombinant C1-Inhibitor: Effects on Coagulation and Fibrinolysis in Patients with Hereditary Angioedema

By Relan Anurag

BioDrugs, Vol. 26, Iss. 1, 2012-02 ,pp. : 43-52

Adis International

Access to resources Recommend Favorite

Human C1-Esterase Inhibitor Concentrate (Berinert®)

By Keating Gillian M.

BioDrugs, Vol. 23, Iss. 6, 2009-12 ,pp. : 399-406

Adis International

Access to resources Recommend Favorite

Nanofiltered Human C1 Inhibitor Concentrate (Cinryze®): In Hereditary Angioedema

By Lyseng-Williamson Katherine A.

BioDrugs, Vol. 25, Iss. 5, 2011-10 ,pp. : 317-327

Adis International

Access to resources Recommend Favorite

Therapeutic application of C1 esterase inhibitor concentrate for clinical amniotic fluid embolism: a case report

Clinical Case Reports, Vol. 3, Iss. 7, 2015-07 ,pp. : 673-675

John Wiley & Sons Inc

Access to resources Recommend Favorite